Replies to post #12 on ShangPharma Corporation (SHP)

[surf1944]

6:01AM ShangPharma and Harbour Antibodies announce licensing agreement (SHP) 7.01 : Co announced that they have entered into a collaborative licensing agreement under which ShangPharma will develop therapeutic antibody candidates for its customers using Harbour's transgenic mouse-based fully human antibody development technology. Harbour will provide ShangPharma with human immunoglobulin-gene transgenic mice for use at the Company's Shanghai facility, where researchers will provide fully human antibody development services to ShangPharma's pharmaceutical clients.